| TERTIARY STRUCTURE DATA |
|
Homo sapiens
|
| inhibitor domain |
1.50 Å |
1AAP |
1AAP |
1AAP |
1AAP |
1AAP |
1AAP |
Hynes et al., 1990 |
| NMR structure of residues 1-28 |
0.00 Å |
1AMB |
1AMB |
1AMB |
1AMB |
1AMB |
1AMB |
Talafous et al., 1994 |
| NMR structure of residues 1-28 |
0.00 Å |
1AMC |
1AMC |
1AMC |
1AMC |
1AMC |
1AMC |
Talafous et al., 1994 |
| NMR structure of residues 1-40 |
0.00 Å |
1AML |
1AML |
1AML |
1AML |
1AML |
1AML |
Sticht et al., 1995 |
| NMR structure of residues 1-40 |
0.00 Å |
1BA4 |
1BA4 |
1BA4 |
1BA4 |
1BA4 |
1BA4 |
Coles et al., 1998 |
| NMR structure of residues 1-40 |
0.00 Å |
1BA6 |
1BA6 |
1BA6 |
1BA6 |
1BA6 |
1BA6 |
Watson et al., 1998 |
| NMR structure of residues 1-28 |
0.00 Å |
1BJB |
1BJB |
1BJB |
1BJB |
1BJB |
1BJB |
Poulsen et al., 2000 |
| NMR structure of residues 1-28 |
0.00 Å |
1BJC |
1BJC |
1BJC |
1BJC |
1BJC |
1BJC |
Poulsen et al., 2000 |
| complex with rat trypsin variant |
2.10 Å |
1BRC |
1BRC |
1BRC |
1BRC |
1BRC |
1BRC |
Perona et al., 1993 |
| Complex with bovine chymotrypsin |
0.00 Å |
1CA0 |
1CA0 |
1CA0 |
1CA0 |
1CA0 |
1CA0 |
Scheidig et al., 1997 |
| NMR structure of residues 10-35 |
0.00 Å |
1HZ3 |
1HZ3 |
1HZ3 |
1HZ3 |
1HZ3 |
1HZ3 |
Zhang et al., 2000 |
| N-terminal domain |
1.80 Å |
1MWP |
1MWP |
1MWP |
1MWP |
1MWP |
1MWP |
Rossjohn et al., 1999 |
| NMR structure of residues 25-35 |
0.00 Å |
1QCM |
1QCM |
1QCM |
1QCM |
1QCM |
1QCM |
Kohno et al., 1996 |
| complex with cattle cationic trypsin |
1.80 Å |
1TAW |
1TAW |
1TAW |
1TAW |
1TAW |
1TAW |
Scheidig et al., 1997 |
| complex with coagulation factor XI catalytic domain |
2.60 Å |
1ZJD |
1ZJD |
1ZJD |
1ZJD |
1ZJD |
1ZJD |
Navaneetham et al., 2005 |
| complex with human mesotrypsin |
2.48 Å |
3L33 |
3L33 |
3L33 |
3L33 |
3L33 |
3L33 |
|
| complex with human presequence protease |
2.70 Å |
4NGE |
4NGE |
4NGE |
4NGE |
4NGE |
4NGE |
|
| amyloid-beta 4-10; complex with angiotensin-1 converting enzyme N- domain |
1.90 Å |
5AM8 |
5AM8 |
5AM8 |
5AM8 |
5AM8 |
5AM8 |
|
| amyloid-beta 35-42; complex with angiotensin-1 converting enzyme N- domain |
1.55 Å |
5AMB |
5AMB |
5AMB |
5AMB |
5AMB |
5AMB |
|
| human mesotrypsin in complex with amyloid precursor protein inhibitor variant appi-m17g/i18f/f34v |
1.83 Å |
5C67 |
5C67 |
5C67 |
5C67 |
5C67 |
5C67 |
|
| combinatorial engineering of proteolytically resistant appi variants that selectively inhibit human kallikrein 6 for cancer therapy |
1.85 Å |
5NX1 |
5NX1 |
5NX1 |
5NX1 |
5NX1 |
5NX1 |
|
| combinatorial engineering of proteolytically resistant appi variants that selectively inhibit human kallikrein 6 for cancer therapy |
2.30 Å |
5NX3 |
5NX3 |
5NX3 |
5NX3 |
5NX3 |
5NX3 |
|
| appi variant Thr11Val/Met17Arg/Ile18Phe/Phe34Val; complex with human mesotrypsin |
2.30 Å |
6GFI |
6GFI |
6GFI |
6GFI |
6GFI |
6GFI |
|
| recognition of the amyloid precursor protein by human gamma-secretase |
2.60 Å |
6IYC |
6IYC |
6IYC |
6IYC |
6IYC |
6IYC |
|
|
Mus musculus
|
| NMR structure |
0.00 Å |
2ROZ |
2ROZ |
2ROZ |
2ROZ |
2ROZ |
2ROZ |
Li et al., 2008 |
| NMR structure |
0.00 Å |
2YSZ |
2YSZ |
2YSZ |
2YSZ |
2YSZ |
2YSZ |
Li et al., 2008 |
| NMR structure |
0.00 Å |
2YT0 |
2YT0 |
2YT0 |
2YT0 |
2YT0 |
2YT0 |
Li et al., 2008 |
| NMR structure |
0.00 Å |
2YT1 |
2YT1 |
2YT1 |
2YT1 |
2YT1 |
2YT1 |
Li et al., 2008 |
| complex with DR6 CRD domain |
2.20 Å |
4YN0 |
4YN0 |
4YN0 |
4YN0 |
4YN0 |
4YN0 |
Xu et al., 2015 |
|
Rattus norvegicus
|
| NGYENPTYK peptide; complex with PTB domain of mouse Disabled homolog 1 |
2.45 Å |
1M7E |
1M7E |
1M7E |
1M7E |
1M7E |
1M7E |
Yun et al., 2003 |
| NMR structure; amyloid beta-peptide 28mer |
0.00 Å |
1NMJ |
1NMJ |
1NMJ |
1NMJ |
1NMJ |
1NMJ |
Huang et al., 2004 |
| 9mer peptide; complex with PTB domain of mouse Disabled homolog 1 |
2.30 Å |
1OQN |
1OQN |
1OQN |
1OQN |
1OQN |
1OQN |
Yun et al., 2003 |
| NMR structure |
0.00 Å |
2LI9 |
2LI9 |
2LI9 |
2LI9 |
2LI9 |
2LI9 |
Istrate et al., 2012 |